Currently out of the existing stock ratings of Phil Nadeau, 102 are a BUY (87.93%), 13 are a HOLD (11.21%), 1 are a SELL (0.86%).

Phil Nadeau

Work Performance Price Targets & Ratings Chart

Analyst Phil Nadeau works at TD COWEN with a stock forecast success ratio of 57.54% fulfilled within 257.17 days on average. Previously, Phil Nadeau worked at COWEN.

Phil Nadeau’s has documented 229 price targets and ratings displayed on 22 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on VRTX, Vertex Pharmaceuticals at 09-Jan-2024.

Wall Street Analyst Phil Nadeau

Analyst best performing recommendations are on IMMU (IMMUNOMEDICS).
The best stock recommendation documented was for IMMU (IMMUNOMEDICS) at 4/1/2020. The price target of $30 was fulfilled within 28 days with a profit of $19.86 (195.86%) receiving and performance score of 69.95.

Average potential price target upside

of $45.3 (14.93%) on BIIB (BIOGEN).
of $37.15 (32.83%) on GWPH (GW PHARMACEUTICALS PLC).
of $36.18 (29.51%) on UTHR (UNITED THERAPEUTICS).

ACOR Acorda Therapeutics APLS Apellis Pharmaceuticals BMRN Biomarin Pharmaceutical DVAX Dynavax Technologies GWPH GW Pharmaceuticals plc IMMU Immunomedics NBIX Neurocrine Biosciences VRTX Vertex Pharmaceuticals GNCA Genocea Biosciences LJPC La Jolla Pharmaceutical Co REGN Regeneron Pharmaceuticals GILD Gilead Sciences BIIB Biogen TCDA Tricida AURA Aura Biosciences FREQ Frequency Therapeutics GRPH Graphite Bio ONCE Spark Therapeutics PHAS PhaseBio Pharmaceuticals UTHR United Therapeutics ZFGN Zafgen RYTM Rhythm Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Raghuram Selvaraju (HC WAINWRIGHT)